Literature DB >> 6333247

Adjuvant low dose radiation in childhood T cell leukaemia/lymphoma (report from the United Kingdom Childrens' Cancer Study Group--UKCCSG).

M G Mott, J M Chessells, M L Willoughby, J R Mann, P H Morris-Jones, J S Malpas, M K Palmer.   

Abstract

From November 1977 to July 1983, 82 children with T leukaemia/lymphoma entered a randomised trial of combination chemotherapy and radiotherapy. Twenty-five were designated T lymphoma and 57 T leukaemia, 28 having greater than 100 x 10(9)1(-1) blasts in peripheral blood at diagnosis. Twenty-seven patients with mediastinal primaries who were treated on the companion non-Hodgkin lymphoma (NHL) trial were comparable in all respects to the T lymphoma patients and the results of treatment were therefore combined and analysed together. Overall 4-year survival (48-53%) and failure-free survival (FFS) (37-40%) were similar in all groups except the 28 with T leukaemia and WCC greater than 100 X 10(9)1(-1) (20% and 13%). There was a significant advantage in FFS for patients randomised to receive low dose mediastinal radiation, and this was most marked in patients with T lymphoma (66% vs 18%, P = 0.006).

Entities:  

Mesh:

Year:  1984        PMID: 6333247      PMCID: PMC1976909          DOI: 10.1038/bjc.1984.201

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  10 in total

1.  Undifferentiated lymphoma, non-Burkitt's type. Meningeal and bone marrow involvement in children.

Authors:  A Watanabe; M P Sullivan; W W Sutow; J R Wilbur
Journal:  Am J Dis Child       Date:  1973-01

2.  Childhood non-Hodgkin's lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2).

Authors:  J R Anderson; J F Wilson; D T Jenkin; A T Meadows; J Kersey; R R Chilcote; P Coccia; P Exelby; J Kushner; S Siegel; D Hammond
Journal:  N Engl J Med       Date:  1983-03-10       Impact factor: 91.245

3.  Non-Hodgkin's lymphoma in children. A comparative study of two modalities of therapy.

Authors:  N Wollner; J H Burchenal; P H Lieberman; P Exelby; G D'Angio; M L Murphy
Journal:  Cancer       Date:  1976-01       Impact factor: 6.860

4.  LSA2-L2 protocol treatment of stage IV non-Hodgkin's lymphoma in children with partial and extensive bone marrow involvement.

Authors:  L Duque-Hammershaimb; N Wollner; D R Miller
Journal:  Cancer       Date:  1983-07-01       Impact factor: 6.860

5.  Modified LSA2-L2 treatment in 53 children with E-rosette-positive T-cell leukemia: results and prognostic factors (a Pediatric Oncology Group Study).

Authors:  D J Pullen; M P Sullivan; J M Falletta; J M Boyett; G B Humphrey; K A Starling; V J Land; P G Dyment; T Vats; M H Duncan
Journal:  Blood       Date:  1982-11       Impact factor: 22.113

6.  Lymphoblastic lymphoma: late relapse in childhood.

Authors:  P L Levine; F R Berberich; J S Burke; M G Mott; J R Wilbur
Journal:  Med Pediatr Oncol       Date:  1983

7.  Monoclonal antibody characterization of surface antigens in childhood T-cell lymphoid malignancies.

Authors:  M Roper; W M Crist; R Metzgar; A H Ragab; S Smith; K Starling; J Pullen; B Leventhal; A A Bartolucci; M D Cooper
Journal:  Blood       Date:  1983-05       Impact factor: 22.113

8.  Clinical, haematological, and radiological features of children presenting with lymphoblastic mediastinal masses.

Authors:  P M Mathew; D R Prangnell; A J Cole; F G Hill; K J Shah; P H Jones; J Martin; M K Palmer; E N Thompson; O B Eden; M G Mott; J R Mann
Journal:  Med Pediatr Oncol       Date:  1980

9.  Acute lymphoblastic leukaemia in children: Classification and prognosis.

Authors:  J M Chessells; R M Hardisty; N T Rapson; M F Greaves
Journal:  Lancet       Date:  1977 Dec 24-31       Impact factor: 79.321

Review 10.  Analysis of the clinical and biological significance of lymphoid phenotypes in acute leukemia.

Authors:  M F Greaves
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

  10 in total
  15 in total

1.  Survival and endocrine outcome after testicular relapse in acute lymphoblastic leukaemia.

Authors:  R G Grundy; A D Leiper; R Stanhope; J M Chessells
Journal:  Arch Dis Child       Date:  1997-03       Impact factor: 3.791

2.  Patterns of care and survival for children with acute lymphoblastic leukaemia diagnosed between 1980 and 1994.

Authors:  C A Stiller; E M Eatock
Journal:  Arch Dis Child       Date:  1999-09       Impact factor: 3.791

3.  UKALL X--an effective treatment for stage III mediastinal non-Hodgkin's lymphoma.

Authors:  K Wheeler; J M Chessells
Journal:  Arch Dis Child       Date:  1990-03       Impact factor: 3.791

4.  Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer.

Authors:  M M Hawkins; L M Wilson; M A Stovall; H B Marsden; M H Potok; J E Kingston; J M Chessells
Journal:  BMJ       Date:  1992-04-11

5.  Growth hormone treatment of growth failure secondary to total body irradiation and bone marrow transplantation.

Authors:  A Papadimitriou; M Urena; G Hamill; R Stanhope; A D Leiper
Journal:  Arch Dis Child       Date:  1991-06       Impact factor: 3.791

6.  Centralisation of treatment and survival rates for cancer.

Authors:  C A Stiller
Journal:  Arch Dis Child       Date:  1988-01       Impact factor: 3.791

7.  Remission death in acute lymphoblastic leukaemia: a changing pattern.

Authors:  A Atra; S M Richards; J M Chessells
Journal:  Arch Dis Child       Date:  1993-11       Impact factor: 3.791

8.  Treatment centre size, entry to trials, and survival in acute lymphoblastic leukaemia.

Authors:  C A Stiller; G J Draper
Journal:  Arch Dis Child       Date:  1989-05       Impact factor: 3.791

9.  Growth following single fraction and fractionated total body irradiation for bone marrow transplantation.

Authors:  B C Thomas; R Stanhope; P N Plowman; A D Leiper
Journal:  Eur J Pediatr       Date:  1993-11       Impact factor: 3.183

10.  Causes of death in children diagnosed with non-Hodgkin's lymphoma between 1974 and 1985.

Authors:  C M Robertson; C A Stiller; J E Kingston
Journal:  Arch Dis Child       Date:  1992-11       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.